Truist Financial Reiterates “Hold” Rating for Doximity (NYSE:DOCS)

Doximity (NYSE:DOCS)‘s stock had its “hold” rating restated by investment analysts at Truist Financial in a research report issued on Thursday,Benzinga reports. They presently have a $19.00 target price on the stock, down from their previous target price of $29.00. Truist Financial’s target price would suggest a potential upside of 6.87% from the company’s previous close.

DOCS has been the topic of a number of other research reports. Robert W. Baird restated a “neutral” rating and issued a $18.00 target price (down from $40.00) on shares of Doximity in a research note on Thursday. Piper Sandler upped their target price on Doximity from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Royal Bank Of Canada restated an “outperform” rating and issued a $44.00 target price on shares of Doximity in a research note on Monday, March 9th. BMO Capital Markets lowered their target price on Doximity from $25.00 to $20.00 and set a “market perform” rating on the stock in a research note on Thursday. Finally, Loop Capital set a $31.00 target price on Doximity in a research note on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.71.

Doximity Stock Down 24.0%

Shares of DOCS traded down $5.61 during mid-day trading on Thursday, reaching $17.78. The company had a trading volume of 9,081,873 shares, compared to its average volume of 3,503,497. Doximity has a 52-week low of $17.15 and a 52-week high of $76.51. The firm has a market capitalization of $3.28 billion, a PE ratio of 14.63, a P/E/G ratio of 1.88 and a beta of 1.36. The company has a 50 day moving average price of $24.27.

Doximity announced that its Board of Directors has approved a share buyback plan on Thursday, February 5th that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to repurchase up to 8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Doximity

In other news, Director Kira Scherer Wampler sold 9,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $26.06, for a total value of $234,540.00. Following the completion of the sale, the director directly owned 19,839 shares in the company, valued at $517,004.34. This represents a 31.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $25.77, for a total transaction of $59,502.93. Following the completion of the sale, the insider owned 89,396 shares of the company’s stock, valued at $2,303,734.92. This trade represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 18,055 shares of company stock valued at $456,061 over the last quarter. Company insiders own 31.30% of the company’s stock.

Hedge Funds Weigh In On Doximity

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Doximity by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock worth $588,281,000 after buying an additional 518,916 shares in the last quarter. William Blair Investment Management LLC lifted its position in Doximity by 11.7% during the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock worth $426,404,000 after buying an additional 609,775 shares in the last quarter. Capital World Investors lifted its position in Doximity by 5.1% during the fourth quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock worth $250,398,000 after buying an additional 273,444 shares in the last quarter. Franklin Resources Inc. lifted its position in Doximity by 6.2% during the third quarter. Franklin Resources Inc. now owns 3,357,505 shares of the company’s stock worth $245,601,000 after buying an additional 194,912 shares in the last quarter. Finally, Invesco Ltd. lifted its position in Doximity by 4.2% during the fourth quarter. Invesco Ltd. now owns 2,426,819 shares of the company’s stock worth $107,460,000 after buying an additional 98,519 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted EPS of $0.26, topping one analyst estimate, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. Doximity Earnings Report
• Positive Sentiment: The company highlighted strong profitability, including a 37.54% net margin and 23.84% return on equity, which supports its high-margin business model. Fiscal Q4 Earnings Snapshot
• Neutral Sentiment: Insider Siddharth Sitaram sold 2,309 shares, but the transaction was part of a pre-arranged 10b5-1 plan and tied to tax withholding from equity vesting, making it less concerning than a discretionary sale. Insider Sale Disclosure
• Negative Sentiment: Investors focused on the fact that Doximity missed broader earnings expectations, with EPS of $0.26 versus the Zacks consensus of $0.28, which suggests the quarter was not as strong as headline results implied. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: More importantly, management’s FY2027 and Q1 FY2027 revenue guidance came in below Wall Street estimates, fueling concerns about slowing growth and higher spending related to AI investments. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: Brokerage firms also turned more cautious, with BMO Capital Markets cutting its price target to $20 and Mizuho lowering its target to $26, reinforcing the weaker sentiment around the stock. Analyst Price Target Changes

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.